



# The Use of HTRF in Biologics Discovery

Liz England
Scientist I
Department of Antibody Discovery and Protein Engineering

HTRF Symposium 26<sup>th</sup> April 2013

### Overview

Benefits of HTRF in Biologics discovery

2 Assay formats employed at MedImmune

Case study – Anti IL-6 antibody

4 Summary



## Profile of a Therapeutic Antibody

Therapeutic Antibody						
Function						
Mechanism of Action						
Affinity						
Specificity						
Species Cross-reactivity						
Lack of toxicity - on target						
- off target						
Chemical, thermal and structural stability						
Novelty						




## Profile of a Therapeutic Antibody

Therapeutic Antibody						
Function						
Mechanism of Action						
Affinity						
Specificity						
Species Cross-reactivity						
Lack of toxicity - on target						
- off target						
Chemical, thermal and structural stability						
Novelty						



### **Lead Generation Workflow**



## Benefits of HTRF in Biologics Discovery

- ♦ Homogeneous
  - Reduces assay variability
  - Reduces assay development time
  - Reduces hands on lab time
- High throughput
  - Routinely use 384 well
  - Low volume assays (10μL)
- Available 'toolbox' reagents
- Sensitive assay format
- ◆ Tolerance to unpurified antibody samples
  - Bacterial and mammalian cell expressed
- Adaptable format for many targets




## **Adaptable Formats**


Direct Antibody Binding

Receptor:Ligand Binding

Co-receptor: Ligand Binding



**Direct Labelling** 





#### Points to Consider

#### Pros

#### Direct Labelling

- Minimal reagent addition steps
- Avoids unwanted tag effects
- Can facilitate use of very low concentrations of reagents

#### Indirect Labelling

- Toolbox reagents available
- Maximise assay flexibility

#### Cons

- Effects of labelling on biological activity
- Batch variation
- Non-homogeneous labelling

- Can require pre-incubation of reagent and detection pairs
- Possible 'tag' effects
- Possibility of steric hindrance
- ◆ Some detection reagent or tag pairs can't be used, e.g. anti-Human Fc if inhibitor is a human IgG, anti-Flag in combination with anti-mouse Fc
- The orientation of donor and acceptor can be optimised for specific assay requirements




## **Assay Formats for HTS**

#### **Direct Binding**

- Simplest form of HTRF Assay
- Measures binding of antibody to antigen
- Will observe hook effect as detection reagent becomes saturated




Anti-Fc XL665



#### Receptor-Ligand Inhibition

- Competition Assay
- Measures binding of ligand to receptor
- Measures inhibition of interaction by competing antibodies




#### **Epitope Competition**

- Competition Assay
- Measures binding of antibody to antigen
- Measures inhibition of interaction by competing antibodies



Anti-Fc XL665





## Profile of a Therapeutic Antibody

Therapeutic Antibody						
Function						
Mechanism of Action						
Affinity						
Specificity						
Species Cross-reactivity						
Lack of toxicity - on target						
- off target						
Chemical, thermal and structural stability						
Novelty						




### **Cross-Reactivity**


#### Ligand receptor assays

- E.g. human ligand:human receptor versus cyno ligand:cyno receptor
- Use in parallel single point screening assays and for potency determination

#### Epitope competition assay format

- Compares ability to bind to antigen with a single assay format
- Fold difference between species for toxicology purposes







Data produced by Carl Matthews



## Specificity






Data produced by Caz Colley

- ◆ Epitope competition assay format
- Confirm antibody specificity
- Early screen for potential off target affects




## **Epitope Binning**



- ◆ Assay set up to measure binding of Ab3 to antigen
- Compete in all antibodies
- ◆ Ab1 and Ab4 have overlapping epitope relative to Ab3
- Ab2 has a completely different epitope to Ab3




## **Viral Inhibition Assay**



- HTRF assay designed to detect inhibitors of the HRV-ICAM:1 interaction
  - Good correlation to viral infectivity assay



### Identification of Inhibitors of HRV Infection






## **Enzyme Activity Assays**

Step 1 = IgG cleavage reaction




Step 2 = HTRF residual IgG quantification






Data produced by Phil Newton


## Case Study: Anti-IL6 Antibody Mechanism of Action









## Identifying Alternative Mechanisms of Action Screening Assays









## Lead Optimisation – Epitope Competition Assay





#### **Epitope Competition Assay**






Data produced by Jamie Campbell


## Improving Assay Sensitivity to Identify High Affinity Antibodies

#### Parent Epitope Competition HTS


5.0% sample (approx 2-20nM scFv)




1.25% sample (approx 0.5-5nM scFv)




0.3% sample (approx 0.12-1.2nM scFv)



0.08% sample (approx 0.03-0.32nM scFv)






Data produced by Jamie Campbell

- Lack of discrimination of very high affinity antibodies
- Caused by antibody depletion or too much IL6 in assay
  - Decrease [IL6]
  - Increase [bio-lgG]
- Limited by amount concentrations can be varied




## **Second Generation Assays**



Assay	Affinity (nM)	[IL6] (nM)	[Bio-lgG] (nM)	[bio-lgG] relative to K <sub>D</sub>	K <sub>i</sub> scFv (nM)	IC <sub>50</sub> scFv (nM)
Parent	20	0.05	2	x 0.1	0.1	0.11
Higher Affinity	0.1	0.05	2	x 20	0.1	2.1

Cheng Prusoff – 
$$K_i = IC_{50}$$
  
 $1 + [L]$   
 $K_D$ 


## Second Generation Assays Enables Differentiation of Higher Affinity ScFv



- ◆ Antibodies identified with affinity increased by >10,000x
  - < pM affinity</pre>



## Improving Assay Sensitivity to Identify High Affinity Antibodies – Example 2



- Second generation epitope competition assays
- ◆ Enable differentiation of most potent antibodies



## HTRF: Providing a Robust, Versatile Platform for Biologics Discovery

**Therapeutic Antibody** IL-6 IL-6 **Function Direct Binding** Mechanism of Action C5a:C3a:C4a Receptor:Ligand **Affinity** Specificity **Enzyme Activity** Human:cyno: rat:mouse **Species Cross-reactivity** Viral Inhibition Lack of toxicity - on target - off target **Epitope Binning** Chemical, thermal and structural stability **Novelty** 



Use of HTRF assays